GW&K Investment Management LLC Sells 18,982 Shares of AtriCure, Inc. (NASDAQ:ATRC)

GW&K Investment Management LLC decreased its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 1.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 981,523 shares of the medical device company's stock after selling 18,982 shares during the period. GW&K Investment Management LLC owned 1.98% of AtriCure worth $31,664,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of ATRC. Invesco Ltd. boosted its holdings in AtriCure by 0.8% in the 4th quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after purchasing an additional 334 shares during the period. Perkins Capital Management Inc. raised its position in shares of AtriCure by 1.3% in the 4th quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock valued at $927,000 after buying an additional 400 shares in the last quarter. State of Wyoming raised its position in shares of AtriCure by 21.9% in the 4th quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock valued at $76,000 after buying an additional 446 shares in the last quarter. LPL Financial LLC raised its position in shares of AtriCure by 5.4% in the 4th quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock valued at $350,000 after buying an additional 584 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of AtriCure by 0.7% in the 4th quarter. Swiss National Bank now owns 95,800 shares of the medical device company's stock valued at $2,928,000 after buying an additional 700 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

Insider Activity at AtriCure

In other news, insider Vinayak Doraiswamy sold 2,500 shares of the stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $33.44, for a total value of $83,600.00. Following the completion of the sale, the insider owned 73,550 shares in the company, valued at $2,459,512. This represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.50% of the stock is currently owned by corporate insiders.

AtriCure Stock Up 2.0%

NASDAQ ATRC traded up $0.59 on Friday, hitting $30.76. 99,645 shares of the company were exchanged, compared to its average volume of 562,128. The company has a market cap of $1.52 billion, a PE ratio of -37.86 and a beta of 1.56. AtriCure, Inc. has a 12 month low of $20.20 and a 12 month high of $43.11. The stock has a fifty day moving average of $32.30 and a 200-day moving average of $34.31. The company has a current ratio of 4.11, a quick ratio of 2.88 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative net margin of 7.95% and a negative return on equity of 5.68%. The business had revenue of $123.62 million for the quarter, compared to analyst estimates of $122.92 million. During the same period in the prior year, the firm earned ($0.28) earnings per share. AtriCure's revenue was up 13.5% on a year-over-year basis. As a group, analysts forecast that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wall Street Zen cut shares of AtriCure from a "buy" rating to a "hold" rating in a research report on Sunday, June 1st. Canaccord Genuity Group decreased their price target on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. UBS Group decreased their price target on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. JPMorgan Chase & Co. decreased their price target on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, March 27th. Finally, Needham & Company LLC reduced their price objective on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, AtriCure has a consensus rating of "Moderate Buy" and an average price target of $50.67.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.